Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system

Diabetes

Volumn 64, Issue 10, 2015, Pages 3406-3412

  Daniele, Giuseppe ^a   Iozzo, Patricia ^b   Molina Carrion, Marjorie ^a   Lancaster, Jack ^a   Ciociaro, Demetrio ^b   Cersosimo, Eugenio ^a   Tripathy, Devjit ^a   Triplitt, Curtis ^a   Fox, Peter ^a   Musi, Nicolas ^a   Defronzo, Ralph ^a   Gastaldelli, Amalia ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; FLUORODEOXYGLUCOSE F 18; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; VENOM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GLUCOSE ABSORPTION; GLUCOSE BRAIN LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HUMAN; HYPOTHALAMUS; INSULIN BLOOD LEVEL; MALE; METABOLIC RATE; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; REWARD; URINE VOLUME; BRAIN; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; IMPAIRED GLUCOSE TOLERANCE; METABOLISM;

BLOOD GLUCOSE; CEREBRUM; CROSS-OVER STUDIES; DIABETES MELLITUS; DOUBLE-BLIND METHOD; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; PREDIABETIC STATE; VENOMS;

EID: 85047289216     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1718     Document Type: Article

References (21)

1. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014;221:T1-T16
2. Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011;8:418-431
3. Alvarez E, Martínez MD, Roncero I, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005;92:798-806
4. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagonlike peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-18
5. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819-837
6. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14
7. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
8. Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013;56:156-161
9. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012;13:33
10. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003;27:313-318
11. Schlögl H, Kabisch S, Horstmann A, et al. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 2013;36:1933-1940
12. Lerche S, Brock B, Rungby J, et al. Glucagon-like peptide-1 inhibits bloodbrain glucose transfer in humans. Diabetes 2008;57:325-331
13. Gejl M, Egefjord L, Lerche S, et al. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab 2012;32:2146-2152
14. Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014;124:2456-2463
15. Matsuda M, Liu Y, Mahankali S, et al. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 1999;48:1801-1806
16. Navarro M, Rodriquez de Fonseca F, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996;67:1982-1991
17. Yang XJ, Kow LM, Pfaff DW, Mobbs CV. Metabolic pathways that mediate inhibition of hypothalamic neurons by glucose. Diabetes 2004;53:67-73
18. Hussain S, Richardson E, Ma Y, et al. Glucokinase activity in the arcuate nucleus regulates glucose intake. J Clin Invest 2015;125:337-349
19. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther 2012;136:82-93
20. Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999;48:1915-1921
21. Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002;51:3384-3390